GOTHENBURG, Sweden--(BUSINESS WIRE)--Regulatory News: Vitrolife (STO:VITR): A total of 22 patients have been recruited to the study, which has been designed in consultation with the FDA, (the US Food and Drug Administration). The results of the study will be reported within a few months.
